NOTICE CONCERNING THE CHANGE OF THE DISTRIBUTION COMPANY FROM AVENTIS PHARMA TO EISAI FOR “ACTONEL 2.5 MG TABLETS” OF AJINOMOTO
Ajinomoto Co., Inc.
Aventis Pharma Ltd.
Eisai Co., Ltd.
Aventis Pharma Ltd., part of the sanofi-aventis Group (President: Philippe Fauchet, Headquarters: Tokyo), Eisai Co., Ltd. (President: Haruo Naito, Headquarters: Tokyo) and Ajinomoto Co., Inc. (President: Norio Yamaguchi, Headquarters: Tokyo) announced today the change of the distribution company for osteoporosis treatment Actonel (generic name: risedronate sodium) for which Ajinomoto has the marketing approval rights in Japan, from Aventis Pharma to Eisai, starting October 1, 2005.
Actonel is the only bisphosphonate agent proven by large-scale clinical trials to reduce the frequency of clinical fractures of the vertebrae and other bones after just six months of administration. In addition, it is also the only such medication confirmed as effective by a large-scale clinical trial focused on evaluation of femoral neck fracture frequency. Since its initial launch in 2000, Actonel has received approval in 92 countries globally.